High Tower Advisors, LLC Tyme Technologies, Inc. Transaction History

High Tower Advisors, LLC

$64.2 Billion
Q2 2024

Shares

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 12, 2022	SELL	$0.28 - $0.68 $3,360 - $8,160	-12,000 Reduced 3.39%	342,000 $120,000
Q4 2021 Feb 10, 2022	SELL	$0.6 - $1.04 $8,460 - $14,664	-14,100 Reduced 3.83%	354,000 $213,000
Q2 2021 Aug 06, 2021	BUY	$1.14 - $1.87 $2,280 - $3,740	2,000 Added 0.55%	368,100 $464,000
Q1 2021 May 10, 2021	SELL	$1.34 - $3.53 $56,816 - $149,672	-42,400 Reduced 10.38%	366,100 $651,000
Q4 2020 Feb 10, 2021	SELL	$0.87 - $1.26 $1,740 - $2,520	-2,000 Reduced 0.49%	408,500 $498,000
Q3 2020 Nov 13, 2020	BUY	$0.93 - $1.35 $30,690 - $44,550	33,000 Added 8.74%	410,500 $401,000
Q2 2020 Aug 10, 2020	SELL	$0.97 - $1.7 $4,850 - $8,500	-5,000 Reduced 1.31%	377,500 $501,000
Q1 2020 May 21, 2020	BUY	$0.9 - $1.95 $11,250 - $24,375	12,500 Added 3.38%	382,500 $421,000
Q4 2019 Feb 14, 2020	BUY	$1.0 - $1.49 $5,000 - $7,450	5,000 Added 1.37%	370,000 $516,000
Q3 2019 Nov 12, 2019	BUY	$0.97 - $1.77 $24,250 - $44,250	25,000 Added 7.35%	365,000 $433,000
Q4 2017 Feb 14, 2018	BUY	$3.25 - $7.3 $1.11 Million - $2.48 Million	340,000	340,000 $2.17 Million

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.